Back

BofA nearly doubles Icotyde’s peak psoriasis sales forecast to $4.5 billion

Verifying
  • Bank of America raised Johnson & Johnson’s Icotyde sales forecast and stock price target.
  • Icotyde’s psoriasis peak-sales estimate rose to $4.5 billion from $2.4 billion.
  • Johnson & Johnson’s third-quarter sales estimate is $25.5 billion, with results due October 13.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.